Navigation Links
SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite
Date:8/5/2009

MUMBAI, India, Aug. 5 /PRNewswire/ -- SIRO Clinpharm, a global, full service Contract Research Organization (CRO) founded in India, today announced the successful completion of the implementation phase of the Oracle Life Science Application Suite (OLSAS) by going live with Oracle Siebel Clinical Trial Management System and Oracle Adverse Events Reporting System.

"We are excited to have the rollout of the entire OLSAS as per our plan for the India operations," said Dr. Ajit Nair, President, India Operations, SIRO Clinpharm. "This will help us manage critical tasks in clinical operations and drug safety in an efficient and globally compliant manner, thus providing our clients the best of technology support to run trials more efficiently."

After this implementation, SIRO gains complete operational functionality of the Oracle suite. SIRO, in April, had gone live with the industry standard Oracle Clinical and Oracle RDC, integrated with TMS for its Clinical Data Management Services.

The OLSAS product portfolio for SIRO is comprised of Siebel Clinical Trial Management System 8.0 (CTMS), Adverse Events Reporting System 4.6 (AERS), Oracle Clinical 4.5.3 (OC), Remote Data Capture 4.5.3 (RDC) and Thesaurus Management System 4.6 (TMS).

SIRO plans to roll out the OLSAS to its European operations soon to have the system working in all geographies in which the company has operations.

About SIRO

SIRO Clinpharm Private Limited (SIRO) is among one of the leading global Clinical Research Organizations (CROs), offering full scope services, conducting clinical trials in the pharmaceutical, biotechnology and medical devices sectors in compliance with international standards. SIRO is one of the first CROs founded in India, which caters to the needs of pharmaceutical companies across the world. The company has offices in India, USA, Israel and in Germany, Romania, Estonia and Greece. SIRO has recently opened offices in Czech Republic & Spain.


'/>"/>
SOURCE SIRO Clinpharm
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
3. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
4. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
5. Potentia Pharmaceuticals POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
6. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
7. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
8. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
9. QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
10. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
11. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... CLEVELAND , April 26, 2016 ... is forecast to expand 4.9 percent annually to ... and other healthcare facilities to decrease rates of ... infection prevention supplies, equipment, and services.  Although declining, ... is significantly above targeted levels set by the ...
(Date:4/26/2016)... DUBLIN , April 26, 2016 ... 3.83 billion before interest, taxes, depreciation and amortization. The ... from the German multinational,s best-selling drugs Xarelto and Eylea, ... the coming years. Xarelto,s patent expiration date was extended ... The global pharmaceuticals market is expected to reach a ...
(Date:4/26/2016)... 26, 2016 According ... Market Size, Share, Development, Growth and Demand ... Product (Consumables, Instruments and Software and Services), ... by Application (Diagnostic Application, Food and Beverage ... by End User (Hospitals, Pharmaceutical & Biotech ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... ... stage this week. A group of researchers and leaders from Sanford Health were ... Regenerative Medicine and Its Cultural Impact ” and receive the 2016 Pontifical Key ...
(Date:4/28/2016)... ... April 28, 2016 , ... University of New England President Danielle N. Ripich ... president of Student Engagement. In addition to his role as director of Athletics, ... , “In the space of just one year Jack has distinguished himself by ...
(Date:4/28/2016)... West Palm Beach, FL (PRWEB) , ... April 28, 2016 , ... ... time for the spring season. Smart pots are frequently used by professional organic farmers ... time for growers to order their supply of fabric pots. Our goal is to ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... at VitaFoods 2016. , Nominated in the Healthy Ageing category, Cognizin® is being ... safety. The Healthy Ageing division can include everything from antioxidants, lipids, proteins, and ...
(Date:4/28/2016)... Phoenix, AZ (PRWEB) , ... ... ... of the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , today announced ... The platform will provide efficient access to medical knowledge, educational resources, and ...
Breaking Medicine News(10 mins):